Kathleen P. Gallagher - 01 May 2025 Form 4 Insider Report for Avidity Biosciences, Inc. (RNA)

Role
Chief Program Officer
Signature
/s/ John B. Moriarty, Jr., J.D., Attorney-in-Fact
Issuer symbol
RNA
Transactions as of
01 May 2025
Net transactions value
-$92,505
Form type
4
Filing time
02 May 2025, 19:55:34 UTC
Previous filing
03 Apr 2025
Next filing
04 Jun 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Gallagher Kathleen P. Chief Program Officer C/O AVIDITY BIOSCIENCES, INC., 10578 SCIENCE CENTER DR., SUITE 125, SAN DIEGO /s/ John B. Moriarty, Jr., J.D., Attorney-in-Fact 02 May 2025 0002048409

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RNA Common Stock Options Exercise $97,819 +5,875 +12% $16.65 56,429 01 May 2025 Direct F1
transaction RNA Common Stock Sale $190,324 -5,875 -10% $32.40 50,554 01 May 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RNA Stock Option (Right to Buy) Options Exercise $0 -5,875 -17% $0.000000 28,471 01 May 2025 Common Stock 5,875 $16.65 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This option exercise and sale was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 12, 2024.
F2 This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $31.46 to $32.99. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 This option was granted on July 18, 2022 and vests in equal installments of 1/48 of the original number of shares subject to the option on each monthly anniversary of such grant date, until it is fully vested and exercisable on July 18, 2026.